The VOICE trial presented at ASN Kidney Week 2026 demonstrated that vadadustat, an oral anemia treatment for dialysis patients, provides better safety outcomes than erythropoiesis-stimulating agents (ESA). Vadadustat reduced hospitalizations by 10%, maintained more stable hemoglobin levels, and caused fewer serious adverse events. Approved by the FDA in 2024, vadadustat is positioned to become a new standard of care for anemia in chronic kidney disease patients on dialysis. This trial involved over 2,100 patients and confirmed both non-inferiority and superiority of vadadustat over ESA in key safety measures.
The VOICE trial on vadadustat safety outcomes provides context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 26, 2026 19:02 WIB: of 150 priced US health-sector stocks, 78 rose and 48 fell. Notable movers include ABCL at USD 12.00 (+1.52%), XRAY at USD 9.57 (+1.48%), and IOVA at USD 14.29 (+1.42%).
Vita Coco, a leading coconut water brand, has partnered with Homesick to create a limited-edition candle collection inspired by Vita Coco Treats flavors: Strawberries & Creme and Frosted Lemonade. The candles capture the essence of these flavors thro...
Neo Security has named Scott Stout as its new Chief Revenue Officer to lead global revenue growth and expand sales of its agentic software security platform. Stout brings over 20 years of cybersecurity experience, including leadership roles at Cisco ...
ThredUp's 2026 Holiday Resale Report reveals that 62% of Americans intend to buy secondhand gifts this holiday season, with 55% preferring unique, vintage items over brand-new ones. Shoppers are allocating about 37% of their gift budget to secondhand...
Senseonics Holdings has begun the first human clinical trial of Freedom, a next-generation continuous glucose monitoring (CGM) system designed without an external on-body transmitter. This implantable device communicates directly with mobile devices ...
Kratos Defense & Security Solutions announced it will release its third quarter 2026 financial results after market close on November 5, 2026. The company will hold a conference call at 2:00 p.m. Pacific Time to discuss its operations and financial p...
